

Instructions for Authors 2017

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online only and open access (effective January 2017) with Stanford University HighWire Press

ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Effectiveness of Analogues of the GS-Nitroxide, JP4-039, as Total Body Radiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. KRAINZ, X. ZHANG, P. WIPF, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Wound Healing is Delayed in the ZSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (*St. Paul, MN; Indianapolis, IN, USA*)

Active and Passive Immunization Against *Staphylococcus aureus* Periprosthetic Osteomyelitis in Rats. N.H.SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (*Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA*)

Effective Mediastinal Lymphadenectomy for Esophageal Cancer Using Slender Tracheal Forceps in Prone Position Thoracoscopic Esophagectomy. M. NAKAJIMA, M. TAKAHASHI, Y. DOMEKI, H. SATOMURA, H. MUROI, M. KIKUCHI, H. OGATA, S. YAMAGUCHI, K. SASAKI, M. SAKAI, M. SOHDA, T. MIYAZAKI, H. KUWANO, H. KATO (*Mibu; Maebashi, Japan*)

A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (*California; Pittsburgh, PA; Newark, NJ, USA*)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (*Copenhagen, Denmark*)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSES, H. SAKAGAMI (*Saitama, Japan*)

Polymorphism in Murine mtATP8 Gene Correlates with Decreased Reactive Oxygen Species in Aging Hematopoietic Cells. C. ROOLF, C. KRETZSCHMAR, K. TIMMER, A. SEKORA, G. KNÜBEL, H.M. ESCOBAR, G. FUELLEN, S.M. IBRAHIM, M. TIEDGE, S. BALTRUSCH, S. MÜLLER, R. KÖHLING, C. JUNGHANSS (*Rostock, Germany*)

Induction of TGF- β by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITAI, S. INABA (*Nara, Japan*)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C.C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSENG, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (*Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC*)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (*Odense; Copenhagen, Denmark*)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUKLAND (*Tromsø; Bodø, Norway*)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (*Jackson, MS, USA*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website www.cgp.iarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (*Spokane, WA; Duarte, CA, USA*)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (*Basel, Switzerland*)

EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6 Expressing MDA-MB-231 Cells. C. JOHNSON, B. SEGOVIA, R.P. KANDPAL (*Pomona, CA, USA*)

Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (*Los Angeles, CA; Boston, MA, USA; London, UK*)

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (*Basel, Switzerland*)

Association of BIM Deletion Polymorphism and BIM- γ RNA Expression in NSCLC with EGFR Mutation. K. ISOBE, A. KAKIMOTO, T. MIKAMI, K. KABURAKI, H. KOBAYASHI, T. YOSHIZAWA, T. MAKINO, H. OTSUKA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, N. TOCHIGI, A. IYODA, S. HOMMA (*Tokyo, Japan*)

High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (*Vitis vinifera*) in HeLa cells. E.A. MAZZIO, K.F.A. SOLIMAN (*Tallahassee, FL, USA*)

A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. J. LU, M.G. BURNETT, M. SHPAK (*Austin, TX; Cambridge, MA, USA*)

The Impact of HRNPM and SLC1A5 in Pathogenesis and Prognosis in Epithelial Ovarian Cancer. K. BJERSAND, T. SEIDAL, I. SUNDSTRÖM POROMAA, H. ÅKERUD, I. SKIRNISDOTTIR (*Uppsala; Halmstad, Sweden*)

Characterization of Heparan Sulfate Proteoglycan-positive Recycling Endosomes Isolated from Glioma Cells. K.A. PODYMA-INOUE, T. MORIWAKI, A.R. RAJAPAKSHE, K. TERASAWA, M. HARA-YOKOYAMA (*Tokyo, Japan*)

Overexpression of HPV16 E6* Alters β -Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells. W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (*Loma Linda, CA, USA*)

Subscription Order Form 2017

- Please enter a Subscription to ANTICANCER RESEARCH Volume 37 (2017).
Annual subscription rates (2017): Institutional, US\$ 1898.00 online, US\$ 2277.00 online & print; Personal, US\$ 897.00 online; US\$ 1277.00 online & print; Prices include rapid delivery and insurance.
2017 online subscriptions include free online access to vol. 24 (2004) - 36 (2016).
- Please send me the following previous volumes (1-36) at 50% discount on the above rates:
- Please invoice.
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

.....

.....

Tel:

Fax: e-mail:

Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2017 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2017 on a basis of priority and availability. Effective from January to December 2017).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 35 years.

- 1981-2016
- 36 volumes
- over 124,000 pages
- over 18,500 original articles
- 928 reviews
- over 85,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:

ANTICANCER RESEARCH, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Special Subscription Order Form 2017

- I am one of the authors of the article published in Anticancer Research Vol....., pp., year
- Please enter my personal subscription to Anticancer Research 2017 (Volume 37) at the special Author's rate of US\$ 465.00 (print or online).
- Please send me previous Volume No(s) at US\$ 224.00 (print) per volume.
- Please send me an invoice.
Prices include rapid delivery and insurance.

Name and address:

.....

.....

Tel-Fax:

e-mail:

Date and signature:

Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer. R. CELIK, R. SEMRAU, C. BAUES, M. TROMMER-NESTLER, W. BAUS, S. MARNITZ (<i>Cologne, Germany</i>)	5285
Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence. M. ISHITOBI, R. FUKUI, Y. HASHIMOTO, N. KITAKA, T. NAKAYAMA, Y. TAMAKI (<i>Osaka, Japan</i>)	5293
Efficacy of Additional Surgical Resection After Endoscopic Submucosal Dissection for Superficial Esophageal Cancer. M. KUDOU, A. SHIOZAKI, H. FUJIWARA, H. KONISHI, K. SHODA, T. ARITA, T. KOSUGA, R. MORIMURA, Y. MURAYAMA, Y. KURIU, H. IKOMA, T. KUBOTA, M. NAKANISHI, K. OKAMOTO, O. DOHI, H. KONISHI, Y. NAITO, E. OTSUJI (<i>Kyoto, Japan</i>).....	5301
Study on the Validity of Pancreaticoduodenectomy in the Elderly. Y. FUTAGAWA, M. KANEHIRA, K. FURUKAWA, H. KITAMURA, S. YOSHIDA, T. USUBA, T. MISAWA, Y. ISHIDA, T. OKAMOTO, K. YANAGA (<i>Tokyo, Japan</i>)	5309
Errata.....	5317

Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experience. G. CICERO, G. LO RE, R. DE LUCA, F. VERNUCCIO, D. PICONE, M. MIDIRI, R. LAGALLA (<i>Palermo, Italy</i>)	5187
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen). G. SCHINZARI, E. ROSSI, G. MAMBELLA, A. STRIPPOLI, R. CANGIANO, M. MUTIGNANI, M. BASSO, A. CASSANO, C. BARONE (<i>Rome; Potenza; Caserta; Milan, Italy</i>)	5193
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer. A. TAMIYA, M. TAMIYA, K. NAKAHAMA, Y. TANIGUCHI, T. SHIROYAMA, S.-I. ISA, T. INOUE, K. OKISHIO, K. NISHINO, T. KUMAGAI, H. SUZUKI, T. HIRASHIMA, F. IMAMURA, S. ATAGI (<i>Osaka, Japan</i>).....	5199
Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposomes. Y. BI, Y. ZHOU, M. WANG, L. LI, R.J. LEE, J. XIE, L. TENG (<i>Changchun; Zhuhai, PR China; Columbus, OH, USA</i>).....	5207
Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. L. CHALISE, K. MOTOMURA, F. OHKA, M. HIRANO, M. HARA, Y. NISHIMURA, A. NATSUME, T. WAKABAYASHI (<i>Nagoya, Japan</i>)	5215
Anti-proliferative, Cytotoxic and NF-κB Inhibitory Properties of Spiro(Lactone-Cyclohexanone) Compounds in Human Leukemia. M.M. BOUHENNA, B. ORLIKOVA, O. TALHI, B. SCHRAM, D.C.G.A. PINTO, N. TAIBI, K. BACHARI, M. DIEDERICH, A.M.S. SILVA, N. MAMERI (<i>Alger; Tipaza, Algeria; Seoul, Republic of Korea; Luxembourg City, Luxembourg; Aveiro, Portugal</i>)	5225
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin. A. MAEDA, H. ANDO, T. URA, K. MURO, M. AOKI, K. SAITO, E. KONDO, S. TAKAHASHI, Y. ITO, Y. MIZUNO, A. FUJIMURA (<i>Nagoya; Tochigi; Niigata, Japan</i>)	5235
Risk-reducing Salpingo–Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. E. RICCIARDI, F. TOMAO, G. ALETTI, L. BAZZURINI, L. BOCCIOLONE, S. BOVERI, F. LANDONI, M.T. LAPRESA, M. MARUCCIO, G. PARMA, F. PECCATORI, M.C. PETRELLA, V. ZANAGNOLO, N. COLOMBO, A. MAGGIONI (<i>Milan, Italy</i>)	5241
The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity. N. YAMASHITA, E. TOKUNAGA, H. YAMAMOTO, C. SHIMIZU, K. TAKETANI, Y. INOUE, H. SAEKI, E. OKI, Y. MAEHARA (<i>Fukuoka; Tokyo, Japan</i>)	5249
Value of Additional Digital Breast Tomosynthesis for Preoperative Staging of Breast Cancer in Dense Breasts. J. KRAMMER, K. STEPNIOWSKI, C.G. KAISER, J. BRADE, P. RIFFEL, S.O. SCHOENBERG, K. WASSER (<i>Mannheim, Germany</i>)	5255
Are Multiple Tumors of the Parotid Gland Uncommon or Underestimated? A.M. FRANZEN, A. COORDES, C.K. FRANZEN, T. GUENZEL (<i>Neuruppin; Berlin; Leer, Germany</i>).....	5263
Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patients Undergoing Salvage Pancreatectomy. A. ANDREOU, F. KLEIN, R.B. SCHMUCK, D. LEE, M. SINN, T. DENECKE, J. PRATSCHE, M. BAHRA (<i>Berlin, Germany</i>)	5269
Surgical Strategy for T1 Duodenal or Ampullary Carcinoma According to the Depth of Tumor Invasion. A. KOHGA, Y. YAMAMOTO, S. SANO, T. SUGIURA, Y. OKAMURA, T. ITO, R. ASHIDA, H. ISHIWATARI, H. MATSUBAYASHI, K. SASAKI, K. UESAKA (<i>Shizuoka, Japan</i>)	5277

Clinical and Oncological Outcomes of Laparoscopic Lateral Pelvic Lymph Node Dissection in Advanced Lower Rectal Cancer: Single-institution Experience. T. NONAKA, A. FUKUDA, K. MAEKAWA, S. NAGAYOSHI, T. TOKUNAGA, M. TAKATSUKI, T. KITAJIMA, K. TANIGUCHI, H. FUJIOKA (<i>Nagasaki, Japan</i>).....	5095
Inconsistent Reporting Between Meta-analysis Protocol and Publication – A Cross-Sectional Study. ALBERTO F. DELGADO, ANNA F. DELGADO (<i>Uppsala; Stockholm, Sweden</i>).....	5101
Metastatic Microcystic Adnexal Carcinoma with DNA Sequencing Results and Response to Systemic Antineoplastic Chemotherapy. M.-B. CHEN, D.A. LABER (<i>Kunshan, PR China; Tampa, FL, USA</i>).....	5109
Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up. F. AMPIL, S. ELLIKA, A. NANDA, M. VORA (<i>Shreveport, LA, USA</i>).....	5113
Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel. J. VON HARDENBERG, M. SCHWARTZ, T. WERNER, S. FUXIUS, M. MÜLLER, T. FRANGENHEIM, C. BOLENZ, C. WEISS, E. HEINRICH (<i>Mannheim; Herzberg am Harz; Heidelberg; Ludwigshafen; Bruchsal; Goettingen, Germany</i>).....	5117
Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients. K. SONE, T. OGURI, K. ITO, Y. KITAMURA, Y. INOUE, A. TAKEUCHI, S. FUKUDA, O. TAKAKUWA, K. MAENO, T. ASANO, Y. KANEMITSU, H. OHKUBO, M. TAKEMURA, Y. ITO, A. NIIMI (<i>Nagoya, Japan</i>).....	5125
Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy. P. ANNEDE, J. DARREON, A. BENKEMOUCHE, S. VALDENNAIRE, M. TYRAN, B. KAEPPELIN, A. MACAGNO, J. BARROU, L.V. CAGETTI, V. FAVREL, L. MOUREAU-ZABOTTO, L. GONZAGUE, P. FAU, C. CHARGARI, A. TALLET, N. SALEM (<i>Marseille; Villejuif; Bretigny-sur-Orge, France</i>).....	5133
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC. R. HAMAGUCHI, T. OKAMOTO, M. SATO, M. HASEGAWA, H. WADA (<i>Kyoto, Japan; Cleveland, OH, USA</i>).....	5141
Evaluation of Factors Affecting Metastasis for Renal Cell Carcinoma Based on Current Guidelines in Japan. Y. KADONO, S. KAWAGUCHI, T. NOHARA, K. SHIGEHARA, K. NARIMOTO, K. IZUMI, H. IKEDA, H. YAEGASHI, T. MIYAGI, T. NAKASHIMA, C. SETO, A. MIZOKAMI (<i>Kanazawa; Toyama, Japan</i>).....	5147
Neoadjuvant Imatinib Therapy Followed by Intersphincteric Resection for Low Rectal Gastrointestinal Stromal Tumors. M. KANEKO, H. NOZAWA, S. EMOTO, K. MURONO, K. SASAKI, K. OTANI, T. NISHIKAWA, T. TANAKA, T. KIYOMATSU, K. HATA, K. KAWAI, T. WATANABE (<i>Tokyo, Japan</i>).....	5155
Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy. T. SHINTANI, Y. MATSUO, Y. IIZUKA, T. MITSUYOSHI, T. MIZOWAKI, M. HIRAOKA (<i>Kyoto, Japan</i>).....	5161
A Scoring System to Predict the Development of Bone Metastasis After Radical Resection of Colorectal Cancer. A. LI, L. KÄSMANN, D. RADES, C. FU (<i>Shanghai, PR China; Lübeck, Germany</i>).....	5169
Comparison of Postoperative Outcomes Between Laparoscopic and Open Surgery for Colorectal Cancer. K. NEKI, K. ETO, M. KOSUGE, M. OHKUMA, R. NOAKI, R. HASHIZUME, S. SASAKI, Y. SHIRAI, K. YANAGA (<i>Tokyo, Japan</i>).....	5173
Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions. B. WOJTCZAK, B. PULA, A. GOMULKIEWICZ, M. OLBROMSKI, M. PODHORSKA-OKOLOW, P. DOMOSLAWSKI, M. BOLANOWSKI, J. DAROSZEWSKI, P. DZIEGIEL (<i>Wroclaw, Poland</i>).....	5179

Hedgehog Stimulation Suppresses Clonogenicity and Activates NOTCH Signalling in T-lymphoblastic Leukaemia Jurkat Cells. Y. OKUHASHI, M. ITOH, S. TOHDA (<i>Tokyo, Japan</i>).....	5005
Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter? A. SUKOVAS, V. CESNA, A. JASUKAITIENE, G. BARAUSKAS, R.J. NADISAUSKIENE, Z. DAMBRAUSKAS, S. PASKAUSKAS, A. GULBINAS (<i>Kaunas, Lithuania</i>)	5011
<i>Clinical Studies</i>	
Outcomes and Prognostic Factors of Resected Salivary Gland Malignancies: Examining a Single Institution's 12-year Experience. T. GUTSCHENRITTER, M. MACHIORLATTI, S. VESELY, B. AHMAD, W. RAZAQ, M. RAZAQ (<i>Oklahoma City, OK, USA</i>).....	5019
Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer. X. WU, P. REINIKAINEN, M. KAPANEN, T. VIERIKKO, P. RYYMIN, P.-L. KELLOKUMPU-LEHTINEN (<i>Tampere, Finland</i>)	5027
Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. U. USLU, S. SCHLIEP, K. SCHLIEP, M. ERDMANN, H.-U. KOCH, H. PARSCH, S. ROSENHEINRICH, D. ANZENGRUBER, A.K. BOSSERHOFF, G. SCHULER, B. SCHULER-THURNER (<i>Erlangen, Germany; Boston, MA, USA</i>)	5033
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma. A. KUMABE, S. ZENDA, A. MOTEGI, M. ONOZAWA, N. NAKAMURA, T. KOJIMA, H. DAIKO, N. SHIGEMATSU, T. AKIMOTO (<i>Tokyo; Kashiwa, Japan</i>).....	5039
Clinical Significance of Salvage Esophagectomy for Patients with Esophageal Cancer and Factors of Influencing Long-term Survival. M. SOHDA, Y. KUMAKURA, H. SAITO, K. KURIYAMA, T. YOSHIDA, H. HONJYO, K. HARA, D. OZAWA, S. SUZUKI, N. TANAKA, M. SAKAI, T. MIYAZAKI, M. FUKUCHI, H. KUWANO (<i>Maebashi, Japan</i>)	5045
Clinicopathological Features of Ductal Carcinoma <i>In Situ</i> from ¹⁸ F-FDG-PET Findings. T. FUJII, K. YANAI, S. TOKUDA, Y. NAKAZAWA, S. KUROSUMI, S. OBAYASHI, R. YAJIMA, T. HIRAKATA, H. KUWANO (<i>Gunma, Japan</i>)	5053
Inflammatory Breast Cancer Outcomes in a Contemporary Series. E. PAN, L. TUNG, O. RAGAB, E. MOROCCO, J. WECSLER, R. SPOSTO, A. RAGHAVENDRA, E. CHUNG, J.E. LANG (<i>Los Angeles, CA, USA</i>)	5057
Detection of Ductal Carcinoma <i>In Situ</i> by Ultrasound and Mammography: Size-dependent Inaccuracy. C. EICHLER, S. ABRAR, J. PUPPE, M. ARNDT, R. OHLINGER, M. HAHN, M. WARM (<i>Cologne; Greifswald; Tuebingen, Germany</i>)	5065
Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer. M. WAKAHARA, T. SAKABE, Y. KUBOUCHI, K. HOSOYA, Y. HIROOKA, Y. YURUGI, K. NOSAKA, T. SHIOMI, H. NAKAMURA, Y. UMEKITA (<i>Tottori, Japan</i>)	5071
MRI and Ultrasound Fusion Imaging for Cervical Cancer. C. THÉODORE, J.M. LEVAILLANT, P. CAPMAS, N. CHABI, D. SKALLI, L. VIENET-LEGUÉ, B. HADDAD, H. FERNANDEZ, C. TOUBOUL (<i>Créteil; Paris, France</i>)	5079
Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer. M. KIM, H. KIM, D.H. SUH, K. KIM, H. KIM, Y.B. KIM, J.H. NO (<i>Seongnam; Seoul, Republic of Korea</i>).....	5087

Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF- κ B Signaling Pathways. H.M. KORASHY, Z.H. MAAYAH, F.E. AL ANAZI, A.M. ALSAAD, I.O. ALANAZI, O.M. BELALI, F.O. AL-ATAWI, A. ALSHAMSAN (<i>Riyadh, Kingdom of Saudi Arabia</i>)	4899
Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF- κ B Activation in Osteosarcoma U2OS Cells. P.-J. PAN, J.-J. TSAI, Y.-C. LIU (<i>Yilan; Taipei; Taichung, Taiwan, ROC</i>)	4911
Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells. F.-T. HSU, C.-C. SUN, C.-H. WU, Y.-J. LEE, C.-H. CHIANG, W.-S. WANG (<i>Taipei; Yilan; New Taipei City; Kaohsiung, Taiwan, ROC</i>)	4919
An Adaptation System to Avoid Apoptosis <i>via</i> Autophagy Under Hypoxic Conditions in Pancreatic Cancer Cells. S. OWADA, K. ITO, H. ENDO, Y. SHIDA, C. OKADA, T. NEZU, M. TATEMACHI (<i>Isehara, Japan</i>)	4927
Critical Overview of HER2 Assessment in Bladder Cancer: What Is Missing for a Better Therapeutic Approach? A.M. CIMPEAN, V. TARLUI, A.A. CUMPĂNAȘ, S. BOLINTINEANU, A. CUMPĂNAȘ, M. RAICA (<i>Timisoara, Romania</i>)	4935
GRP78 Regulates Apoptosis, Cell Survival and Proliferation in 5-Fluorouracil-resistant SNUC5 Colon Cancer Cells. J.H. LEE, Y.M. YOON, S.H. LEE (<i>Birmingham, AL, USA; Seoul; Cheonan, Republic of Korea</i>)	4943
The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to <i>KRAS</i> Gene Status. J.K. BAR, A. LIS-NAWARA, P. GRELEWSKI, L. NOGA, Z. GRZEBIENIAK, M. JELEŃ (<i>Wroclaw, Poland</i>)	4953
The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients. K. ORYWAL, W. JELSKI, T. WEREL, M. SZMITKOWSKI (<i>Bialystok, Poland</i>)	4961
The Impact of Environmental Light Intensity on Experimental Tumor Growth. M.A. SUCKOW, W.R. WOLTER, G.E. DUFFIELD (<i>St. Paul, MN; Notre Dame, IN, USA</i>)	4967
The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes in Breast Cancer in Taiwan. A.-K. CHOU, C.-L. HSIAO, T.-C. SHIH, H.-C. WANG, C.-W. TSAI, W.-S. CHANG, L.-C. LIU, T.-D. WAY, J.-G. CHUNG, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	4973
Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer. T. SHIMURA, M. SHIBATA, K. GONDA, Y. KOFUNATO, R. OKADA, T. ISHIGAME, T. KIMURA, A. KENJO, K. KONO, S. MARUBASHI (<i>Fukushima, Japan</i>)	4979
Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells. H. ONISHI, K. NAKAMURA, S. NAGAI, K. YANAI, A. YAMASAKI, M. KAWAMOTO, A. IMAIZUMI, T. MORISAKI (<i>Fukuoka; Tokyo, Japan</i>)	4987
Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning – A Phantom Study. J. WIKSTROM, U. ISACSSON, B. JOHANSSON, B. LENNERNÄS (<i>Uppsala; Örebro, Sweden</i>)	4993
Role of Caspase-9 Gene Ex5+32 G>A (rs1052576) Variant in Susceptibility to Primary Brain Tumors. S. OZDOGAN, A. KAFADAR, S.G. YILMAZ, O. TIMIRCI-KAHRAMAN, U. GORMUS, T. ISBIR (<i>Istanbul, Turkey</i>)	4997
Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa. S. KASE, K. ISHIJIMA, T. URAKI, Y. SUIMON, Y. SUZUKI, M. KASE, S. ISHIDA (<i>Sapporo, Japan</i>)	5001

Phosphoproteomic Analysis Identifies Signaling Pathways Regulated by Curcumin in Human Colon Cancer Cells. T. SATO, Y. HIGUCHI, Y. SHIBAGAKI, S. HATTORI (<i>Tokyo; Nagoya, Japan</i>).....	4789
Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2. A. KUBAN-JANKOWSKA, K.K. SAHU, M. GORSKA-PONIKOWSKA, J.A. TUSZYNSKI, M. WOZNIAK (<i>Gdansk, Poland; Edmonton, Canada</i>).....	4799
Effective Metabolic Targeting of Human Osteosarcoma Cells <i>In Vitro</i> and in Orthotopic Nude-mouse Models with Recombinant Methioninase. K. IGARASHI, K. KAWAGUCHI, T. KIYUNA, K. MIYAKE, T. MURAKAMI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, H. TSUCHIYA, R.M. HOFFMAN (<i>San Diego, CA, USA; Kanazawa, Japan</i>).....	4807
Probing the Molecular Mechanisms Governing the Oncolytic Activity of <i>Paeonia suffruticosa</i> on Triple-negative Breast Cancer Cells <i>In Vitro</i> . D. KIM, D. RADIN, D. LEONARDI (<i>St. Louis, MO; New York, NY; Hackensack, NJ, USA</i>)	4813
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia. M. VORA, L.A. ALATTIA, J. ANSARI, M. ONG, J. COTELINGAM, D. COPPOLA, R. SHACKELFORD (<i>Shreveport, LA; Tampa, FL, USA</i>).....	4821
Communicate or Die – A Model for HPV+ and HPV– CSCs and Their Interactions with SDF-1 α . F. JUNGBAUER, C. ADERHOLD, R. BIRK, K. HOERMANN, B. KRAMER, B. KUHLIN, C. THORN, C. UMBREIT, A. LAMMERT (<i>Mannheim; Marburg; Jena, Germany</i>)	4827
Role of ARHGAP24 in ADP Ribosylation Factor 6 (ARF6)-dependent Pseudopod Formation in Human Breast Carcinoma Cells. S. UEHARA, K. SAITO, H. ASAMI, Y. OHTA (<i>Kanagawa, Japan</i>)	4837
Increased <i>CXCL8</i> Expression Is Negatively Correlated with the Overall Survival of Patients with ER-Negative Breast Cancer. Q. FANG, X. WANG, G. LUO, M. YU, X. ZHANG, N. XU (<i>Changzhou, PR China; Lund, Sweden</i>)	4845
Transforming Growth Factor- β , Interleukin-10, and Serological Markers in EBV-associated Gastric Carcinoma. D. PACHNIA, B. DROP, A. DWORZAŃSKA, E. KLISZCZEWSKA, M. POLZ-DACEWICZ (<i>Ryki; Lublin, Poland</i>).....	4853
Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy. M. TIMMER, J.-M. WERNER, G. RÖHN, M. ORTMANN, T. BLAU, C. CRAMER, P. STAVRINOU, B. KRISCHEK, P. MALLMAN, R. GOLDBRUNNER (<i>Cologne, Germany</i>)	4859
Circulating Levels of VEGF and <i>CXCL1</i> Are Predictive of Metastatic Organotropism in Patients with Colorectal Cancer. R. DIVELLA, A. DANIELE, R. DE LUCA, M. SIMONE, E. NAGLIERI, E. SAVINO, I. ABBATE, C.D. GADALETA, G. RANIERI (<i>Bari, Italy</i>).....	4867
Bcl-2-like Protein 11 (BIM) Expression Is Associated with Favorable Prognosis for Patients with Cervical Cancer. B.W. KIM, H. CHO, K. YLAYA, H. KITANO, J.-Y. CHUNG, S.M. HEWITT, J.-H. KIM (<i>Bethesda, MD, USA; Incheon; Seoul, Republic of Korea; Otsu, Japan</i>)	4873
Expression of Cancer Stem Cell-associated <i>DKK1</i> mRNA Serves as Prognostic Marker for Hepatocellular Carcinoma. T. SAKABE, J. AZUMI, Y. UMEKITA, K. TORIGUCHI, E. HATANO, Y. HIROOKA, G. SHIOTA (<i>Yonago; Kyoto, Japan</i>)	4881
Induction and Analysis of Cytotoxic T-Lymphocytes that Recognize Autologous Oral Squamous Cell Carcinoma. J.-Y. OKAMOTO, A. MIYAZAKI, J.-I. KOBAYASHI, S. MIYAMOTO, T. SASAKI, T. KANASEKI, Y. HIROHASHI, T. TORIGOE, H. HIRATSUKA (<i>Sapporo, Japan</i>)	4889